TRIM21 and myositis disease: Marie et al. failed to show a significant difference regarding progression of ILD between patients with and without anti-Ro52 antibody and concluded the association of more severe myositis, joint impairment, and increased risk of cancer with the coexistence of anti-Ro52 antibody in anti-Jo-1 positive patients [22].